Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment.

Nanoparticle-based therapeutics are poised to become a leading delivery strategy for cancer treatment because they potentially offer higher selectivity, reduced toxicity, longer clearance times, and increased efficacy compared to conventional systemic therapeutic approaches. This article reviews existing nanoparticle technologies and methods that are used to target drugs to treat cancer by altering signal transduction or modulating the tumor microenvironment. We also consider the implications of recent advances in the nanotherapeutics field for the future of cancer therapy.

[1]  Robert Langer,et al.  New frontiers in nanotechnology for cancer treatment. , 2008, Urologic oncology.

[2]  Donald E Ingber,et al.  Cell tension, matrix mechanics, and cancer development. , 2005, Cancer cell.

[3]  John Maraganore,et al.  A status report on RNAi therapeutics , 2010, Silence.

[4]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[5]  On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[6]  Jinsong Liu,et al.  Tumor stroma as targets for cancer therapy. , 2013, Pharmacology & therapeutics.

[7]  G. P. Agrawal,et al.  Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis , 2011, Journal of drug targeting.

[8]  Han-Sung Kim,et al.  Tumor-targeting gold particles for dual computed tomography/optical cancer imaging. , 2011, Angewandte Chemie.

[9]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[10]  Robert Langer,et al.  Nanoparticle technologies for cancer therapy. , 2010, Handbook of experimental pharmacology.

[11]  D. Mukhopadhyay,et al.  Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. , 2005, Cancer cell.

[12]  Michael Pedersen,et al.  Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells. , 2013, Nanoscale.

[13]  B. Unsworth,et al.  Breast Cancer: Induction of Differentiation by Embryonic Tissue , 1973, Science.

[14]  S. Parveen,et al.  Polymeric nanoparticles for cancer therapy , 2008, Journal of drug targeting.

[15]  D. Ingber,et al.  Breast cancer normalization induced by embryonic mesenchyme is mediated by extracellular matrix biglycan. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[16]  S. Dhar,et al.  Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics , 2012, Proceedings of the National Academy of Sciences.

[17]  Shawn M. Douglas,et al.  A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads , 2012, Science.

[18]  L. Vitale,et al.  Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity1 , 2007, The Journal of Immunology.

[19]  Y. DeClerck,et al.  Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. , 2013, Cancer research.

[20]  D. Ingber,et al.  Basement membrane as a spatial organizer of polarized epithelia. Exogenous basement membrane reorients pancreatic epithelial tumor cells in vitro. , 1986, The American journal of pathology.

[21]  S. Dhar,et al.  Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. , 2013, ACS nano.

[22]  Zongxi Li,et al.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.

[23]  Fabian Kiessling,et al.  Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. , 2013, Current opinion in biotechnology.

[24]  A. Verkman,et al.  Enhanced macromolecule diffusion deep in tumors after enzymatic digestion of extracellular matrix collagen and its associated proteoglycan decorin , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[25]  M. Morris,et al.  Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics , 2009, British journal of pharmacology.

[26]  P. Limtrakul,et al.  Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment , 2011, Archives of pharmacal research.

[27]  A. K. Suresh,et al.  Matrix metalloproteinase-triggered denuding of engineered gold nanoparticles for selective cell uptake. , 2013, Journal of materials chemistry. B.

[28]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[29]  Hao Yan,et al.  Challenges and opportunities for structural DNA nanotechnology. , 2011, Nature nanotechnology.

[30]  C. Lok,et al.  The transferrin receptor: role in health and disease. , 1999, The international journal of biochemistry & cell biology.

[31]  R. Mumper,et al.  Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. , 2010, Nanomedicine.

[32]  R. Markwald,et al.  Hyaluronan–CD44 interactions as potential targets for cancer therapy , 2011, The FEBS journal.

[33]  Yi-Chun Chen,et al.  Multifunctional nanomicellar systems for delivering anticancer drugs. , 2014, Journal of biomedical materials research. Part A.

[34]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[35]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[36]  D. Ingber,et al.  Reconstituting Organ-Level Lung Functions on a Chip , 2010, Science.

[37]  M. Ferrari,et al.  A Theoretical Model for the Margination of Particles within Blood Vessels , 2005, Annals of Biomedical Engineering.

[38]  Zena Werb,et al.  Stromal Effects on Mammary Gland Development and Breast Cancer , 2002, Science.

[39]  D. Ingber,et al.  Self-assembly of 3D prestressed tensegrity structures from DNA , 2010, Nature nanotechnology.

[40]  M. D. Blanco,et al.  Folate-Targeted Nanoparticles Based on Albumin and Albumin/Alginate Mixtures as Controlled Release Systems of Tamoxifen: Synthesis and In VitroCharacterization , 2013, Pharmaceutical Research.

[41]  S. Sorrenti,et al.  The urokinase plasminogen activator system: a target for anti-cancer therapy. , 2009, Current cancer drug targets.

[42]  Kazuo Maruyama,et al.  Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. , 2008, International journal of pharmaceutics.

[43]  R. Steinman,et al.  Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy , 2010, Immunology and cell biology.

[44]  Hong Yuan,et al.  Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. , 2013, Colloids and surfaces. B, Biointerfaces.

[45]  D E Ingber,et al.  Role of basal lamina in neoplastic disorganization of tissue architecture. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Robin A. J. Smith,et al.  Delivery of bioactive molecules to mitochondria in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Shuming Nie,et al.  Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer , 2009, Clinical Cancer Research.

[48]  I. Fichtner,et al.  A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. , 2003, Cancer research.

[49]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[50]  E. Moase,et al.  ADVENTURES IN TARGETING , 2002, Journal of liposome research.

[51]  Mary E Napier,et al.  PRINT: a novel platform toward shape and size specific nanoparticle theranostics. , 2011, Accounts of chemical research.

[52]  P. Sommer,et al.  Lysyl oxidase-like protein localizes to sites of de novo fibrinogenesis in fibrosis and in the early stromal reaction of ductal breast carcinomas. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[53]  S. Nie,et al.  Nanotechnology applications in cancer. , 2007, Annual review of biomedical engineering.

[54]  R. C. Siegel.  Lysyl oxidase. , 1979, International review of connective tissue research.

[55]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[56]  S. Ko,et al.  Colorimetric assay of matrix metalloproteinase activity based on metal-induced self-assembly of carboxy gold nanoparticles. , 2013, Biosensors & bioelectronics.

[57]  Michael S. Goldberg,et al.  Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression , 2012, The Journal of experimental medicine.

[58]  V. Torchilin.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.

[59]  K. Kataoka,et al.  Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles , 2009, Cancer science.

[60]  R. D'Amato,et al.  An orally delivered small-molecule formulation with antiangiogenic and anticancer activity , 2008, Nature Biotechnology.

[61]  H. Tsukada,et al.  Anti‐neovascular therapy by liposomal drug targeted to membrane type‐1 matrix metalloproteinase , 2004, International journal of cancer.

[62]  S. Sahoo,et al.  Efficacy of transferrin‐conjugated paclitaxel‐loaded nanoparticles in a murine model of prostate cancer , 2004, International journal of cancer.

[63]  P. Sharp,et al.  Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells , 2010, Proceedings of the National Academy of Sciences.

[64]  K. Kiguchi,et al.  EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[65]  X. Qian,et al.  Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles , 2012, International journal of nanomedicine.

[66]  M. Tiwari.  Nano cancer therapy strategies. , 2012, Journal of cancer research and therapeutics.

[67]  Ulrich Beyer,et al.  Liposomal encapsulated anti-cancer drugs. , 2005, Anti-cancer drugs.

[68]  Ronnie H. Fang,et al.  Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles. , 2013, Nanoscale.

[69]  B. Frisch,et al.  Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes. , 2008, Bioconjugate chemistry.

[70]  Joo H. Kang,et al.  Inhibition of mammary tumor growth using lysyl oxidase-targeting nanoparticles to modify extracellular matrix. , 2012, Nano letters.

[71]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[72]  Zhiyuan Zhong,et al.  Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. , 2013, Biomaterials.

[73]  Pushpa Mishra,et al.  Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. , 2007, Nanomedicine : nanotechnology, biology, and medicine.

[74]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[75]  A. Rodríguez-Sinovas,et al.  Lysyl oxidase as a potential therapeutic target. , 2008, Drug news & perspectives.

[76]  T. Behnke,et al.  Targeted luminescent near-infrared polymer-nanoprobes for in vivo imaging of tumor hypoxia. , 2011, Analytical chemistry.

[77]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  C. de Lange Davies,et al.  Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx™) in human osteosarcoma xenografts , 2005, British Journal of Cancer.

[79]  R. China,et al.  The CD 47-signal regulatory protein alpha ( SIRPa ) interaction is a therapeutic target for human solid tumors , 2012 .

[80]  J. Zink,et al.  In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[81]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[82]  E. Grigorieva,et al.  Expression of different proteoglycans in human breast tumors , 2007, Biochemistry (Moscow).

[83]  D. Mooney,et al.  Biomaterial-Based Vaccine Induces Regression of Established Intracranial Glioma in Rats , 2011, Pharmaceutical Research.

[84]  Itamar Willner,et al.  DNA nanotechnology: from sensing and DNA machines to drug-delivery systems. , 2013, ACS nano.

[85]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[86]  Erkki Ruoslahti,et al.  Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. , 2003, Cancer cell.

[87]  F. Szoka,et al.  Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. , 2008, Molecular pharmaceutics.

[88]  Paula T Hammond,et al.  Layer-by-layer nanoparticles with a pH-sheddable layer for in vivo targeting of tumor hypoxia. , 2011, ACS nano.

[89]  E. A. Sykes,et al.  Tumour-on-a-chip provides an optical window into nanoparticle tissue transport , 2013, Nature Communications.

[90]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[91]  A. Noel,et al.  Targeting the tumor microenvironment for cancer therapy. , 2013, Clinical chemistry.

[92]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[93]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[94]  Betty Y. S. Kim,et al.  Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. , 2008, Nano letters.

[95]  S. Ganta,et al.  Role of integrated cancer nanomedicine in overcoming drug resistance. , 2013, Advanced drug delivery reviews.

[96]  J. Benoit,et al.  Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells , 2011, Pharmaceutical Research.

[97]  Samir Mitragotri,et al.  Particle shape enhances specificity of antibody-displaying nanoparticles , 2013, Proceedings of the National Academy of Sciences.

[98]  G. Storm,et al.  Targeting tumor antigens to dendritic cells using particulate carriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[99]  Daniel C Leslie,et al.  A Human Disease Model of Drug Toxicity–Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice , 2012, Science Translational Medicine.

[100]  G. Ge,et al.  Lysyl Oxidase, Extracellular Matrix Remodeling and Cancer Metastasis , 2012, Cancer Microenvironment.

[101]  W. S. Vanden Berg-Foels,et al.  Bioengineering strategies for designing targeted cancer therapies. , 2013, Advances in cancer research.

[102]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[103]  S. V. Sreenivasan,et al.  Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms , 2013, Proceedings of the National Academy of Sciences.

[104]  Amy Brock,et al.  Silencing HoxA1 by Intraductal Injection of siRNA Lipidoid Nanoparticles Prevents Mammary Tumor Progression in Mice , 2014, Science Translational Medicine.

[105]  C. Xie,et al.  Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. , 2006, Cancer letters.

[106]  Michael S. Goldberg,et al.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery , 2012, Proceedings of the National Academy of Sciences.

[107]  David J. Mooney,et al.  Infection-Mimicking Materials to Program Dendritic Cells In Situ , 2008, Nature materials.

[108]  D. Ingber.  Tensegrity II. How structural networks influence cellular information processing networks , 2003, Journal of Cell Science.

[109]  P. Oh,et al.  Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung , 2007, Nature Biotechnology.

[110]  M. Neeman,et al.  Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. , 2003, Cancer research.

[111]  Eun-Kyung Lim,et al.  Efficient CD44-targeted magnetic resonance imaging (MRI) of breast cancer cells using hyaluronic acid (HA)-modified MnFe2O4 nanocrystals , 2013, Nanoscale Research Letters.

[112]  Mei Rosa Ng,et al.  A stiff blow from the stroma: collagen crosslinking drives tumor progression. , 2009, Cancer cell.

[113]  Guangjun Nie,et al.  Nanotechnological strategies for therapeutic targeting of tumor vasculature. , 2013, Nanomedicine.

[114]  H. Kuh,et al.  The reciprocal interaction: chemotherapy and tumor microenvironment. , 2011, Current drug discovery technologies.

[115]  Mingqian Tan,et al.  Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging. , 2010, Biomacromolecules.

[116]  Y. Shimada,et al.  Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  Umer Rashid,et al.  Nanomaterials in combating cancer: therapeutic applications and developments. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[118]  Bumsoo Han,et al.  Multifaceted transport characteristics of nanomedicine: needs for characterization in dynamic environment. , 2013, Molecular pharmaceutics.

[119]  Linyong Zhu,et al.  Highly Discriminating Photorelease of Anticancer Drugs Based on Hypoxia Activatable Phototrigger Conjugated Chitosan Nanoparticles , 2013, Advanced materials.

[120]  Sylvia Wagner,et al.  Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. , 2008, Bioconjugate chemistry.

[121]  R. J. Kelleher,et al.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. , 2009, Clinical immunology.

[122]  Z. Duan,et al.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[123]  Robert Langer,et al.  Targeted nanoparticles for cancer therapy , 2007 .

[124]  Samir Mitragotri,et al.  Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium , 2013, Proceedings of the National Academy of Sciences.

[125]  J. Davies,et al.  Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470 , 2004, Nature Medicine.

[126]  Eun-Kyung Lim,et al.  Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment , 2008, Biotechnology and bioengineering.

[127]  K. Berg,et al.  Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. , 2008, Journal of biomedical materials research. Part A.

[128]  W. T. Beck,et al.  Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells , 2008, Journal of Pharmacology and Experimental Therapeutics.

[129]  Robert Langer,et al.  Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.

[130]  Nicholas A Peppas,et al.  Targeted Nanodelivery of Drugs and Diagnostics. , 2010, Nano today.

[131]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[132]  Galo J. A. A. Soler-Illia,et al.  Hyaluronan degrading silica nanoparticles for skin cancer therapy. , 2013, Nanoscale.

[133]  V. Vié,et al.  Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[134]  Jun Wang,et al.  Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. , 2011, ACS nano.

[135]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[136]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[137]  K. Claffey,et al.  Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature , 2005, Molecular Cancer Therapeutics.

[138]  Donald E Ingber,et al.  Can cancer be reversed by engineering the tumor microenvironment? , 2008, Seminars in cancer biology.

[139]  Guo-Feng Luo,et al.  Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. , 2013, Biomaterials.

[140]  You Han Bae,et al.  Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[141]  S. Pun,et al.  Increased nanoparticle penetration in collagenase-treated multicellular spheroids , 2007, International journal of nanomedicine.

[142]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[143]  A. Oloumi,et al.  Identification of genes differentially expressed in V79 cells grown as multicell spheroids , 2002, International journal of radiation biology.

[144]  A. Lavasanifar,et al.  Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles , 2011, Pharmaceutical Research.

[145]  G. Bendas,et al.  VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. , 2008, Biochimica et biophysica acta.

[146]  L. Claesson-Welsh.  Blood vessels as targets in tumor therapy , 2012, Upsala journal of medical sciences.

[147]  Peter H Watson,et al.  Mammographic density is related to stroma and stromal proteoglycan expression , 2003, Breast Cancer Research.

[148]  R. Kane,et al.  Nanoparticle-mediated cytoplasmic delivery of proteins to target cellular machinery. , 2010, ACS nano.

[149]  J. Xie,et al.  Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. , 2010, Biomaterials.

[150]  V. Labhasetwar,et al.  Targeted Drug Delivery in Cancer Therapy , 2005, Technology in cancer research & treatment.

[151]  Michael S. Goldberg,et al.  Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis , 2009, Proceedings of the National Academy of Sciences.

[152]  P Couvreur,et al.  Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. , 2003, Journal of controlled release : official journal of the Controlled Release Society.